Kim, J.J. and Shaw, O. and Martin, C. and Michaelides, George and Balasubramaniam, R. and Sebire, N.J. and Mamode, N. and Dorling, A. and Vaughan, R. and Marks, S.D. (2018) Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. Pediatric Nephrology 33 (1), pp. 167-174. ISSN 0931-041X.
|
Text
s00467-017-3772-7.pdf - Published Version of Record Available under License Creative Commons Attribution. Download (776kB) | Preview |
Abstract
Introduction We have previously shown that children who developed de novo donor-specific human leukocyte antigen (HLA) antibodies (DSA) had greater decline in allograft function. We hypothesised that patients with complementactivating DSA would have poorer renal allograft outcomes. Methods A total of 75 children developed DSA in the original study. The first positive DSA sample was subsequently tested for C1q and C3d fixing. The primary event was defined as 50% reduction from baseline estimated glomerular filtration rate and was analysed using the Kaplan–Meier estimator. Results Of 65 patients tested, 32 (49%) and 23 (35%) tested positive for C1q and C3d fixing, respectively. Of the 32 C1qpositive (c1q+) patients, 13 (41%) did not show concomitant C3d fixing. The mean fluorescence intensity values of the original immunoglobulin G DSA correlated poorly with complement-fixing positivity (C1q: adjusted R2 0.072; C3d: adjusted R2 0.11; p < 0.05). C1q+ antibodies were associated with acute tubulitis [0.75 ± 0.18 (C1q+) vs. 0.25 ± 0.08 (C1q −) episodes per patient (mean ± standard error of the mean; p < 0.05] but not with worse long-term renal allograft dysfunction (median time to primary event 5.9 (C1q+) vs. 6.4 (C1q−) years; hazard ratio (HR) 0.74; 95% confidence ratio (CI) 0.30–1.81; p = 0.58]. C3d-positive (C3d+) antibodies were associated with positive C4d histological staining [47% (C3d+) vs. 20% (C3d−); p = 0.04] and with significantly worse long-term allograft dysfunction [median time to primary event: 5.6 (C3d+) vs. 6.5 (C3d−) years; HR 0.38; 95% CI 0.15–0.97; p = 0.04]. Conclusion Assessment of C3d fixing as part of prospective HLA monitoring can potentially aid stratification of patients at the highest risk of long-term renal allograft dysfunction.
Metadata
| Item Type: | Article |
|---|---|
| Keyword(s) / Subject(s): | Renal transplant, HLA antibodies, Donor-specific antibodies, Complement fixation, Prognosis |
| School: | Birkbeck Faculties and Schools > Faculty of Business and Law > Birkbeck Business School |
| Depositing User: | George Michaelides |
| Date Deposited: | 27 Sep 2017 12:42 |
| Last Modified: | 02 Aug 2023 17:35 |
| URI: | https://eprints.bbk.ac.uk/id/eprint/19737 |
Statistics
Additional statistics are available via IRStats2.
Archive Staff Only (login required)
